Epstein-Barr virus (EBV)

EBV is associated with a wide range of benign and malignant diseases.

In addition to causing infectious mononucleosis, the Epstein-Barr virus is associated to the etio-pathogenesis of an increasing number of tumors, most importantly Burkitt’s lymphoma and nasopharyngeal carcinoma.1

It is also postulated to be a trigger for some forms of chronic fatigue syndrome,2 as well as multiple sclerosis and other autoimmune diseases.3

Roche enables the rapid, quantitative detection of EBV using polymerase chain reaction (PCR) technology, providing laboratories and healthcare providers with reliable results in under three hours.

References:

  1. Pannone G, Zamparese R, Pace M, et al. The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey. Infect Agent Cancer. 2014;9(1):34.
  2. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. IgM serum antibodies to Epstein–Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. In vivo. 2014;18(2):101–106.
  3. Lünemann JD, Münz C. Epstein–Barr virus and multiple sclerosis. Curr Neurol Neurosci Rep. 2007;7(3):253–258.